Bisoprolol vs Carvedilol
## Overview
Bisoprolol and carvedilol are both guideline-recommended beta-blockers for HFrEF alongside metoprolol succinate XL. Bisoprolol is highly cardioselective; carvedilol is non-selective with additional alpha-1 blockade. Both have mortality benefit from pivotal RCTs.
## Mechanism of Action
Bisoprolol: highly selective beta-1 antagonist. Carvedilol: non-selective beta-1/beta-2 + alpha-1 antagonist plus antioxidant properties.
## Pharmacokinetics
Bisoprolol: bioavailability ~90%, half-life 10–12 h, once daily dosing, dual hepatic/renal elimination. Carvedilol: bioavailability ~25–35%, half-life 7–10 h, twice daily dosing, primarily hepatic.
## Clinical Evidence
Both have Class I recommendations for HFrEF. CIBIS-II (bisoprolol) and US Carvedilol Trials / COPERNICUS (carvedilol) demonstrated ~34–65% mortality reductions. No definitive head-to-head trial has compared the two directly with equivalent doses.
## Pulmonary Considerations
Bisoprolol's high beta-1 selectivity makes it usable cautiously in mild COPD. Carvedilol's beta-2 blockade makes it less suitable for patients with bronchospastic disease.
## Key Takeaways
- Both Class I HFrEF; bisoprolol once-daily, carvedilol twice-daily
- Bisoprolol preferred in COPD/asthma (high cardioselectivity)
- Carvedilol adds vasodilation (alpha-1); bisoprolol does not
Sonuç
Bisoprolol is preferred in patients with co-existing pulmonary disease (COPD) or when once-daily dosing is important for adherence. Carvedilol is preferred when additional vasodilatory effect is desired (high afterload, hypertension-associated HFrEF). Both are equally valid guideline options for HFrEF.